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Abstract
Multi-country randomised clinical trials (MRCTs) are common in the medical lit-
erature and their interpretation has been the subject of extensive recent discussion.
In many MRCTs, an evaluation of treatment effect homogeneity across countries
or regions is conducted. Subgroup analysis principles require a significant test of
interaction in order to claim heterogeneity of treatment effect across subgroups,
such as countries in a MRCT. As clinical trials are typically underpowered for tests
of interaction, overly optimistic expectations of treatment effect homogeneity can
lead researchers, regulators and other stakeholders to over-interpret apparent dif-
ferences between subgroups even when heterogeneity tests are insignificant. In
this paper we consider some exploratory analysis tools to address this issue. We
present three measures derived using the theory of order statistics which can be
used to understand the magnitude and the nature of the variation in treatment
effects that can arise merely as an artefact of chance. These measures are not in-
tended to replace a formal test of interaction, but instead provide non-inferential
visual aids allowing comparison of the observed and expected differences between
regions or other subgroups, and are a useful supplement to a formal test of inter-
action. We discuss how our methodology differs from recently published methods
addressing the same issue. A case study of our approach is presented using data
from the PLATO study, which was a large cardiovascular MRCT that has been
the subject of controversy in the literature. An R package is available from the
authors on request.
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Abstract
Multi-country randomised clinical trials (MRCTs) are common in the med-
ical literature and their interpretation has been the subject of extensive recent
discussion. In many MRCTs, an evaluation of treatment eect homogeneity
across countries or regions is conducted. Subgroup analysis principles require a
signicant test of interaction in order to claim heterogeneity of treatment eect
across subgroups, such as countries in a MRCT. As clinical trials are typically
underpowered for tests of interaction, overly optimistic expectations of treat-
ment eect homogeneity can lead researchers, regulators and other stakeholders
to over-interpret apparent dierences between subgroups even when heterogene-
ity tests are insignicant. In this paper we consider some exploratory analysis
tools to address this issue. We present three measures derived using the the-
ory of order statistics which can be used to understand the magnitude and the
nature of the variation in treatment eects that can arise merely as an artefact
of chance. These measures are not intended to replace a formal test of interac-
tion, but instead provide non-inferential visual aids allowing comparison of the
observed and expected dierences between regions or other subgroups, and are
a useful supplement to a formal test of interaction. We discuss how our method-
ology diers from recently published methods addressing the same issue. A case
study of our approach is presented using data from the PLATO study, which
was a large cardiovascular MRCT that has been the subject of controversy in
the literature. An R package is available from the authors on request.
Keywords: clinical trial; heterogeneity; interaction; multi-country study; subgroup
analysis
1 Introduction
Multi-country randomised clinical trials (MRCTs) evaluating new drug therapies are
popular as they eciently pool resources to provide faster recruitment and more
generalisable results across patient populations, ethnicities and disease management
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paradigms. MRCTs also have the advantage of providing country-specic data that
can be used for local regulatory dossiers that may otherwise require bridging studies,
and local reimbursement applications for countries that have government funded phar-
maceutical schemes. As a supplement to the overall analysis, MRCTs often present
country-specic results that eectively correspond to a subgroup analysis. These sub-
groups may be dened by the individual countries participating in the study, or by
pooling several countries in a geographical region, to avoid issues of low power or ana-
lytical complications that can arise from low enrolment in individual countries. In this
paper we will focus on the interpretation of these country- or region-specic subgroup
analyses, and will use the terms country and region interchangeably.
Clinical trials often assess the consistency of the treatment eect across pre-specied
subgroups and generally accepted principles of subgroup analysis have been developed
[1, 2]. In MRCTs, there is typically an assessment of treatment eect homogeneity
across subgroups dened by regions. According to subgroup analysis principles, a test
of interaction is the standard assessment of treatment eect heterogeneity across sub-
groups. However, as most studies are only designed with adequate power to detect an
overall clinically meaningful dierence between treatments in the primary endpoint, the
test of interaction to assess heterogeneity of treatment eect across regions in a MRCT
can often be underpowered [3, 4]. Indeed, the power decreases further as the number of
regions in the subgroup analysis increases. Therefore, when there is a non-signicant
p-value from a test of interaction in the presence of seemingly heterogeneous treatment
eects across regions, speculation of a type II error can arise making interpretation
of the regional results dicult. It is very important that such speculation takes due
account of the fact that random variation can result in some regions showing a lack
of benet even when there is no underlying heterogeneity and the treatment eect is
benecial. To this end, it is prudent to investigate whether potential dierences exist
between regions that can plausibly lead to dierential treatment benet and to appro-
priately design a study with this in mind [5]. A design paper or the study analysis plan
can also be used to pre-emptively document and help inform researchers of the extent
of chance variation to anticipate in a planned MRCT [6].
Consideration of potential dierences between region-specic treatment eects is
important at both the design stage and the analysis stage of a MRCT. At the design
stage it is useful to understand the nature and extent of chance dierences that can
be expected to arise between regions, under the assumption of treatment eect homo-
geneity. At the analysis stage it is useful to compare the observed regional treatment
dierences with the expected regional treatment dierences and assess the magnitude
of any dierences. As such, the intent of this approach is not to determine how the
methodology performs under heterogeneity. Instead, it assesses the potential extent of
chance variation under an assumption of homogeneity. A previous paper focused on
considerations at the design stage [6], and in the present paper we adapt and extend this
approach for application at the analysis stage. Our methods are based on the theory
of order statistics for heteroscedastic normally distributed variables, which is applied
to the collection of region-specic treatment dierences. This allows various compar-
isons of expected subgroup-specic eects to be made with the actual observed eects
under an assumption of treatment eect homogeneity. Specically, we investigate the
expected and observed eects via a comparison of order statistics, the probability of
subgroups favouring the control, and the distribution of the range of treatment eects.
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The resulting collection of graphical presentations provides a useful supplementary
tool to the test of interaction and can equip researchers with a visual summary of
the concordance between the observed treatment dierences across regions and those
expected due to chance. Although we will focus on regional dierences in MRCTs, the
methodology that we propose is equally applicable to other subgroup analyses.
Over recent years there has been a high level of research activity on statistical
considerations relating to treatment eect heterogeneity in MRCTs and multi-centre
studies, reecting the practical importance of this issue [4, 5, 6, 7, 8, 9, 11, 12, 13].
In the next section we will begin by reviewing past methods of relevance to those dis-
cussed here, including a very recently published approach which, like ours, is based on
the theory of order statistics [13]. We then introduce our methodological extensions, as
well as providing a discussion of the fundamental dierences between our approach and
previous approaches, particularly our use of absolute treatment eects rather than stan-
dardised treatment eects in assessing the concordance between observed and expected
treatment eect heterogeneity. Although this introduces methodological complexities
compared to past approaches [13], we argue that this leads to more interpretable ex-
ploratory analysis tools. Finally we consider a detailed case study of the methods
based on the PLATO study, which was a large MRCT of ticagrelor and clopidogrel
for the prevention of cardiovascular events in patients with acute coronary syndromes
[14]. Application of our methods to the PLATO study, which has been the subject
of much discussion in the literature, suggests that the apparently large variation in
country-specic treatment eects is consistent with the play of chance.
2 Overview of previous research
We begin with an overview of previous work which our research extends, together with
an introduction of the assumptions and notation that will be used throughout the
paper.
2.1 Assumptions
Consider the comparison of two treatment groups, a control treatment group and an
experimental treatment group, in a MRCT conducted over R regions. The sample size
for treatment group i in region r is nir, for i = 1; 2 and r = 1; : : : ; R. It is assumed that
there is a parameter  which measures the treatment eect, with  = 0 corresponding
to no dierence between the treatments. In principle the parameter  could depend
on r, meaning that there is genuine treatment eect heterogeneity across the regions.
However, here we will make the assumption that  does not depend on r, because
our methods are aimed at assessing the extent of chance variation that could arise
in the observed region-specic treatment eects under the assumption that there is
underlying homogeneity.
The treatment eect  could take a variety of forms depending on the type of
primary endpoint that is being used in the MRCT. For example, with continuous
endpoints  may be a mean dierence, with binary endpoints  may be a risk dierence,
log relative risk or log odds ratio, while for time-to-event endpoints  may be a log
hazard ratio. Regardless of the type of treatment eect that  measures, it will be
assumed that for each region there is a region-specic estimator Dr of , which has a
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normal distribution
Dr  N
 
; s2r

r = 1; : : : ; R: (1)
This distributional assumption will be reasonable for most types of treatment eect
measures on an appropriate scale, at least under a large sample assumption with ap-
proximate normality. Furthermore, it is assumed that the region-specic estimators
are independent random variables. Other than these general assumptions it is not
necessary for us to make any specic assumptions about the type of endpoint or the
treatment eect measure . In the case study described in Section 4 we will make
use of the above model with a time-to-event endpoint where  is a log hazard ratio
parameter and Dr are country-specic log-hazard ratio estimators. However, it is also
applicable for other treatment eect measures, and has been used for relative risks and
risk dierences in other contexts [6, 15].
The form of s2r in (1) can be derived in terms of the proportion of the study enrol-
ment allocated to region r and the design parameters used in the overall sample size
calculation, including the power, signicance level and the homogeneous treatment
dierence . This form of sr is useful for the assessment of expected treatment eect
heterogeneity at the design stage, as illustrated by Marschner [6]. At the analysis stage
s2r will not be known in general, so a standard error estimate must also be available as
discussed further in Section 3.5.
2.2 Expected range
Marschner [6] proposed the expected range of region-specic treatment eects as a
useful benchmark for the expected treatment eect variation. The expected range can
be derived based on the distribution function of the smallest and largest order statistics,
D(1) and D(R), which are respectively
F(1)(x) = 1 
RY
i=1
f1  Fi(x)g = 1 
RY
i=1

1  

x  
si

and
F(R)(x) =
RY
i=1
Fi(x) =
RY
i=1


x  
si

:
Here, Fi is the distribution function of the normal distribution in equation (1) with
r = i, while  is standard normal distribution function.
Using these distribution functions, the expectations of D(1) and D(R) can be calcu-
lated, as can the expectation of the range of treatment eects, V = D(R) D(1) [6]. The
expectation E(V ) provides a measure of the range of the treatment dierences that
can be expected due to chance, under an assumption of treatment eect homogeneity
across the regions. The intent of this measure was to facilitate a comparison of the
range of observed and expected treatment dierences, thus providing a non-inferential
complement to the primary assessment based on a test of interaction of treatment ef-
fect dierences across regions. Subsequently the expected range has also been used
in a more inferential capacity by Chen et al. [13], although this was not the original
intention.
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2.3 Probability of at least one region favouring the control
An alternative measure that is also based on the extreme order statistics and provides
information about the expected variation in region-specic treatment eects is the
probability of at least one region favouring the control [6, 16]. The motivation for
considering this quantity is that an inconsistent region-specic treatment eect in a
study that shows an overall benet in favour of the experimental treatment will often
prompt further investigation and interpretation. Quantifying the probability of this
event, and the extent to which it is likely or unlikely, therefore provides a benchmark
against which the occurrence of an inconsistent region-specic treatment eect can be
interpreted.
Assuming  is scaled such that a negative value for the treatment dierence indicates
benet in favour of the experimental treatment, then the probability of at least one
region favouring the control is given by
Pr
 
D(R) > 0

= 1 
RY
i=1
Fi(0) = 1 
RY
i=1

 
si

:
As with the expected range, the intent of this measure is to provide a non-inferential
tool to calibrate expectations about whether all treatment eects should lie in a consis-
tent direction. If the probability is substantial, then it should not be too surprising if an
inconsistent treatment eect is observed in a particular region, and over-interpretation
of such an observation should be avoided. Such information can be taken into consid-
eration alongside the test of interaction.
2.4 Normal scores
While the extreme order statistics D(1) and D(R) provide information about treatment
eect heterogeneity, it is natural to consider more informative methods based on all
order statistics. A recently proposed alternative approach of Chen et al. [13] does
this. This approach assesses treatment eect heterogeneity using normal probability
plots comparing the ordered standardised treatment dierences with their associated
normal scores. Specically, the approach uses the standardised quantity referred to as
the weighted least squares residual dened as er = (Dr   ^)=sr. Here
^ =
RX
r=1
wrDr
is an unbiased estimator of  with the weights wr = s
 2
r =
PR
i=1 s
 2
i

reecting the
amount of statistical information provided by region r, or equivalently the precision of
the region-specic estimator Dr. Under the assumption of treatment eect homogene-
ity, the weighted least squares residuals are distributed as
er =
(Dr   ^)
sr
 N 0; 1  wr: (2)
It then follows from (2) that the standardised weighted least squares residual er =
er=
p
1  wr has a standard normal distribution. The method proposes comparing
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the ordered standardised weighted least squares residuals e(r), r = 1; : : : ; R; with the
standard normal scores which can be readily obtained using standard tables or software
[17, 18]. The main tool for undertaking this comparison is a normal probability plot.
In the special case of a homoscedastic normal outcome where  is the mean dierence
and the treatment group sizes are equal within each region, the weights wr reduce to
the proportion of the overall sample size that comes from region r [13]. However, the
above approach applies more generally, and can be used for other treatment dierence
measures that conform with the basic assumption (1).
In the present paper, our most signicant contribution is to adapt this normal scores
method to make use of the absolute order statistics D(r) in place of the standardised
order statistics e(r). In the next section we consider the substantial methodological
complexities this introduces, but also explain why we believe this leads to a more
interpretable assessment of treatment eect heterogeneity.
3 Methodological extensions
In this section we consider various extensions and adaptations of the methods reviewed
in the previous section. We will focus on three measures that can be used in comparing
the observed variation in treatment eects with what would be expected by chance
under the assumption of treatment eect homogeneity across regions.
3.1 Overview of extensions
The rst of the three measures we consider is the expected value of the rth order statistic
of the region-specic treatment eects, E
 
D(r)

, for each r = 1; : : : ; R. Comparison of
these expected order statistics with the sample order statistics D(r), for example using
a normal probability plot, provides an alternative version of the comparison described
in Section 2.4, between e(r) and the normal scores. Although it may seem like a
natural alternative to use of the absolute treatment eects rather than the standardised
treatment eects, this introduces a number of complexities because the D(r) quantities
are the order statistics from a heteroscedastic sample. These complexities are addressed
in the next section. Despite the additional complexity we argue in Section 3.4 that this
comparison provides a preferable assessment of treatment eect heterogeneity than the
use of standardised treatment eects as used by Chen et al. [13].
The second measure involves using the full distribution of the number of regions
that favour the control, rather than the more restrictive quantity discussed in Section
2.3, the probability of at least one region favouring the control. This distribution will
be helpful in interpreting studies where more than one region favours the control, which
is not uncommon in MRCTs involving a large number of regions.
Finally, the third measure we consider is the full probability distribution of the
treatment eect range, D(R)   D(1), which is helpful in interpreting the treatment
eect range observed in a MRCT. Use of the full distribution generalises the expected
range approach described in Section 2.2, which is based just on the expected value
of the eect range distribution. In principle this approach could also be generalised
to other range-based distributions, such as the distribution of the inter-quartile range
of region-specic treatment eects. Here, however, we restrict our focus to the range
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of treatment eects which, as described in Section 2.2, has been the focus of prior
research.
3.2 Order statistic distribution
All of our methods depend fundamentally on the distribution of the order statistics of
the region-specic treatment eects. This involves considering the order statistics from
a sample of R heteroscedastic normal variates. We now consider this distribution and
then describe how it can be used to derive the three measures of expected treatment
eect heterogeneity.
The distribution function of D(r) is
F(r)(x) = Pr
 
D(r)  x

= Pr (At least r of R treatment dierences do not exceed x)
=
RX
i=r
X
S2Si(R)
Y
k2S
Fk(x)
RY
k=1
k=2S

1  Fk(x)

(3)
where Si(R) is the family of all subsets of size i from f1; : : : ; Rg [19].
On expansion and simplication of (3) we get
F(r)(x) =
RX
i=r
cir
X
S2Si(R)
Y
k2S
Fk(x) (4)
where
cir = ( 1)i r

i  1
r   1

:
In the special case where the Drs are independent identically distributed random
variables with sr = s, equation (4) reduces to
F(r)(x) =
RX
i=r
cir

R
i

F (x)i;
and is equivalent to the familiar representation [17]
F(r)(x) =
RX
i=r

R
i

F (x)i

1  F (x)R i:
However, our formulation allows for a fully heteroscedastic specication which is re-
quired to allow for dierent regions having dierent sample sizes.
Applying the product rule for dierentiation on the distribution function, the prob-
ability density of the rth order statistic is
f(r)(x) =
RX
i=r
RX
j=1
cirfj(x)
X
S2Si(R)
1fj 2 Si(R)g
Y
k2S
k 6=j
Fk(x) (5)
where 1fg is the indicator function. Although this theoretical specication appears
unwieldy, it is straightforward to compute.
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As with F(r)(x), a simplied version of (5) is achieved in the special case where the
Drs are independent identically distributed random variables with sr = s, and is given
by
f(r)(x) =
RX
i=r
icir

R
i

f(x)F (x)i 1:
A simplied illustrative example of the order statistic distribution is provided for
a MRCT with R = 3 regions and treatment dierences D1; D2, and D3. In this case,
consider the distribution of D(2). Here, the family of sets S2(3) and S3(3) would be
given by S2(3) = ff1; 2g ; f1; 3g ; f2; 3gg and S3(3) = ff1; 2; 3gg. The distribution and
density functions of D(2) follow readily from (4) and (5) and the fact that c22 = 1 and
c32 =  2, namely
F(2)(x) = F1(x)F2(x) [1  F3(x)] + F1(x)F3(x) [1  F2(x)]
+ F2(x)F3(x) [1  F1(x)] + F1(x)F2(x)F3(x)
= c22  fF1(x)F2(x) + F1(x)F3(x) + F2(x)F3(x)g
+ c32  fF1(x)F2(x)F3(x)g
and
f(2)(x) = c22  ff1(x)F2(x) + f1(x)F3(x) + f2(x)F1(x)
+f2(x)F3(x) + f3(x)F1(x) + f3(x)F2(x)g
+ c32  ff1(x)F2(x)F3(x) + f2(x)F1(x)F3(x) + f3(x)F1(x)F2(x)g :
The forms of F(2)(x) and f(2)(x) in this simplied 3-region example illustrate the link
between equations (3) and (4) and the role of the cir constants in specifying the order
statistic distribution.
As foreshadowed in Section 3.1, the general order statistic distribution for het-
eroscedastic treatment eects can now be used to derive several useful measures of
chance treatment eect variation that extend and improve upon the measures dis-
cussed in Section 2.
3.3 Measures of chance variation
The rst measure described in Section 3.1, the expectation of the rth order statistic of
the region-specic treatment dierences, can now be obtained using (5)
E
 
D(r)

=
Z 1
 1
xf(r)(x)dx: (6)
Although this form is not explicit, it can be straightforwardly computed using standard
routines for numerical integration. As explained later in the paper, all computations
presented here were performed in R [18].
Once computed, these expected order statistics can be compared graphically with
the observed ordered treatment dierences to assess whether the observed spread of
region-specic treatment dierences is unusual relative to what would be expected by
chance under the assumption of treatment eect homogeneity. One such plot would a
simple box plot of the observed and expected order statistics which provides a graphical
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generalisation of the approach of comparing the observed and expected ranges [6]. An-
other approach would be a plot of the observed versus expected treatment dierences,
which is a type of normal probability plot that conveys information about any depar-
tures of the observed region-specic treatment eects from what would be expected by
chance.
Treatment dierences that align consistently across regions in terms of direction
of eect are straightforward to interpret and explain. Sometimes, however, chance
variation will lead some regions to have a treatment eect estimate that goes in the
opposite direction to the overall eect. This can potentially lead to speculation and
over-interpretation. Therefore, being able to compare the observed number of regions
favouring the control with the probability distribution of the number of regions favour-
ing the control provides a useful benchmark by which to assess the role of chance
variation. This leads to the second of the three approaches introduced in Section 3.1,
which generalises the previously suggested approach discussed in Section 2.3.
Like the other quantities discussed in this section, the probability distribution of
W , the number of regions favouring the control, is connected to the order statistic
distribution discussed in Section 3.2 through the relationship
Pr(W  w) = Pr D(R w+1) > 0 = 1  F(R w+1)(0) w = 1; : : : ; R: (7)
Assuming a positive treatment dierence signies an eect in favour of the control
treatment, and letting pi be the probability that region i favours the control, we have
the following
pi = Pr
 
Di > 0

= 1  Fi(0) = 1   ( =si) :
It then follows from equations (3) and (7) that the probability function of the number
of regions favouring the control is
PW (w) = Pr(W = w) = Pr(W  w)  Pr(W  w + 1)
= F(R w)(0)  F(R w+1)(0)
=
X
S2Sw(R)
Y
k2S
pk
RY
l=1
l=2S
(1  pl) w = 0; : : : ; R (8)
where, for notational purposes, we dene F(0)(0) = 1 and F(R+1)(0) = 0. For example,
in the 3-region illustration discussed previously, the probability that two regions favour
the control is
PW (2) = Pr(W = 2) = p1p2(1  p3) + p1p3(1  p2) + p2p3(1  p1):
Once this distribution has been computed, the observed number of regions favouring the
control can be compared with PW (w) in order to assess whether the observed number
is unusual compared with what would be expected by chance under the assumption of
homogeneous treatment eects. A natural summary measure of the extent to which
the observation W = wo is consistent with chance variation, is the probability of
obtaining an observation at least as extreme as W = wo, namely, PE = Pr
 
W  wo

.
Although we are not recommending PE as a p-value for formal hypothesis testing, it
does nonetheless provide a non-inferential quantication of the extent to which the
observed number of inconsistent regions is unusual relative to what would be expected
by chance.
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Finally, the third approach introduced in Section 3.1 is based on the probability
distribution of the range of region-specic treatment eects, V = D(R)   D(1). This
distribution is well known in the homoscedastic case based on the joint distribution
of D(1) and D(R) [17]. In the heteroscedastic generalisation that we are using in this
paper, the density function of the range can be expressed as follows for x  0.
fV (x) =
Z 1
 1
RX
i=1
RX
j=1
j 6=i
fi(y)fj(y + x)
RY
k=1
k 6=i;j
[Fk(y + x)  Fk(y)] dy: (9)
As in equation (6), equation (9) requires numerical integration which we have under-
taken in R using the integrate routine [18]. Once computed, the observed range can
be compared with the probability distribution fV (x) to assess whether the observed
range of treatment eects is unusual relative to what would be expected by chance
under an assumption of treatment eect homogeneity. As with W above, a natural
summary measure of the extent to which the observation V = vo is consistent with
chance variation, is provided by the probability of obtaining an observation at least as
extreme as V = vo, which in this case is PE =
R1
vo
fV (x)dx.
An R package that implements all three approaches can be made available by the
authors on request.
3.4 Comparison of the methods
While our methods and those of Chen et al. [13] both make use of assessments that
are based on the theory of order statistics, there are important dierences between the
two approaches. Most signicantly, our approach uses the observed region-specic
treatment dierences whereas the approach proposed by Chen et al. [13] uses the
standardised treatment dierences in the form of the weighted least squares residuals.
In view of these dierences, a discussion of the distinction between the two approaches
is necessitated.
Statistically, the key distinction between using the absolute order statistics D(r) and
the standardised order statistics e(r), is that the former depends only on the treatment
eects themselves, while the latter depends on a combination of the departure of the
treatment eects from the overall eect and the associated standard error. Therefore,
an ordering of the standardised weighted least squares residuals is essentially an or-
dering of the departure of the treatment eects from the overall eect, relative to the
region-specic standard error, with the size of the standard error playing a critical role
in the ordering. This may mean that the D(r) and e(r) values are ordered in dierent
ways. Indeed, this may mean that the two versions of order statistics convey dierent
messages about whether the observed region-specic treatment eects are consistent
with what would be expected by chance, and we provide an example of this in the case
study discussed in Section 4.
The fact that the absolute and standardised treatment eects can convey dierent
messages makes it important to consider how subgroup analyses are interpreted and
used in practice by stakeholders. While the standardised treatment eects are what
drives the formal test of heterogeneity, they are not the primary focus of subsequent
informal assessments of the region-specic dierences in treatment eects. Such in-
formal assessments, which would typically follow an insignicant test of heterogeneity,
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tend to focus on the absolute magnitudes of the treatment dierence in each region.
The spread in these absolute treatment eects is what then has the potential to lead
to over-interpretation of apparent treatment eect variation. It therefore makes sense
to focus on the expected variation in absolute treatment eects as a benchmark for the
observed variation in absolute treatment eects. It is this use of actual rather than
standardised treatment eects in the assessment and interpretation of heterogeneity
that has led us to base our measures of expected variation on the actual treatment
eects.
3.5 Implementation issues
In practice, there are several implementation issues that we discuss prior to considering
a case study. Firstly, it requires noting that the various quantities discussed in the pre-
vious section are dependent on the unknown values of  and sr. This means that at the
analysis stage of a study, sample estimates ^ and s^i are required so that computations
of the expected variation in treatment eects can be undertaken. If the individual pa-
tient data are available, the overall treatment eect estimated using these data would
be the most appropriate estimate of , as an assumption of treatment eect homo-
geneity underpins the assessment of chance variation. However, if only region-specic
treatment eect estimates are available, the aggregated estimate of , as discussed in
Section 2.4, would be used.
With regards to the standard error si, there are two possible approaches to esti-
mation. The rst, as used in this paper, would be to use the standard errors of the
region-specic treatment eects as estimated separately within each region. This pro-
vides a more empirical estimate of standard error than the second approach which is to
use the overall estimate of standard error, weighted by the proportion of subjects from
each region. The latter approach enforces an assumption of region-level homoscedastic-
ity and results in smaller regions being weighted less and larger regions being weighted
more. This is a more natural approach to take at the design stage when no data is
available.
A further implementation issue relates to the computational complexity of the meth-
ods. In Section 3.3 we presented theoretical expressions associated with the various
measures of heterogeneity, that can be computed exactly with the aid of a routine to
undertake numerical integration. In practice, it is also possible to approximate all of
the required quantities using simulation. Although this is potentially computationally
expensive, the computations themselves are trivial and obvious with the availability of a
large number of simulated samples D1; : : : ; DR from the normal distributions N
 
^; s^2r

,
for r = 1; : : : ; R. Since the theoretical computations required to compute the quanti-
ties described in Section 3.3 are based on combinatorial sets, there will generally be
a point at which simulation becomes more ecient than direct computation. Based
on our experience with the case study described in Section 4, the simulation approach
tends to be preferable for R > 20.
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4 Case study
4.1 PLATO study
As a case study, we consider the PLATO study which was a 43-country, double-blind,
randomised trial comparing the experimental treatment ticagrelor with the control
treatment clopidogrel, for the prevention of cardiovascular events in 18,624 subjects
with acute coronary syndrome [14]. The primary endpoint of this study was the time
to rst occurrence of a cardiovascular event (death from vascular causes, myocardial
infarction, or stroke). The study was designed to have 90% power to detect a relative
risk reduction of 13.5%.
On completion, the overall study showed a signicant reduction in cardiovascular
events in favour of ticagrelor (hazard ratio 0.84, p < 0:001). Treatment eect hetero-
geneity was assessed in 33 separate subgroup analyses, one of which was an assessment
of the heterogeneity of treatment eects across regions (Asia/Australia, Central/South
America, Europe/Middle East/Africa and North America). The p-value for this test
of interaction was 0.045 with the treatment eect in North America having an ob-
served value that favoured the control, although insignicantly so. The investigators
concluded that this nding may have been a chance result due to multiple testing,
and that although no apparent explanations had been found, questioned whether the
dierences between patient populations and treatment practice patterns may have con-
tributed to this result.
Although a p-value of 0.045 in the context of 33 subgroup analyses is not particu-
larly surprising, the PLATO study was subsequently subjected to extensive post hoc
analysis of country-specic heterogeneity in treatment eects. These analyses focused
particularly on the observation that the USA treatment eect was in the direction
favouring the control. The Food and Drug Administration (FDA) conducted its own
review of the data following the sponsor's proposal of a potentially negative association
between the dose of aspirin and the benet of treatment with ticagrelor, nding that
the dose of aspirin was higher in the USA subgroup compared with the non-USA sub-
group [20]. A further review of this possible explanation was subsequently published
together with a claim that dierences in primary site monitoring by an independent
contract research organisation (in the USA) and the study sponsor (in most other coun-
tries) may oer an alternative explanation requiring further investigation [21]. These
proposals of a potential biological explanation (aspirin dose) and an operational ex-
planation (site monitoring) were followed by a statistical assessment concluding that
the country-specic treatment eect variation was consistent with the play of chance
[22] and a further analysis concluding that the ndings in the USA were likely not due
to chance [13]. Here we use our methods to provide further exploration of the play
of chance as a potential explanation for country-specic treatment eect dierences in
the PLATO study.
4.2 Data and analyses
In our analyses, we used published country-specic hazard ratios and 95% condence
intervals for all countries except the smallest (Hong Kong), which had only 16 patients.
This led to R = 42 countries with sample sizes varying from 51 to 2666. We refer the
reader to Figure 1 of Serebruany [21] for a full listing of the countries, sample sizes and
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hazard ratios used in our analyses. The overall treatment eect  was taken to be the
log hazard ratio, for which assumption (1) is reasonable. The overall estimate ^ was
calculated using an inverse variance weighting method based on country-specic log
hazard ratios and standard errors calculated from the published condence intervals.
As well as analyses of the treatment eects for all 42 countries, we also considered
analyses restricted just to the countries with the largest sample sizes. These additional
analyses served two purposes. Firstly, they enabled an assessment of the extent to
which any conclusions are robust to the larger variation expected in small countries,
which was raised as a concern by Chen et al. [13]. Secondly, these analyses served to
illustrate the behaviour of the methodology on data sets having various R values. In
our analyses we consider the results restricted to the largest 10, 15 and 20 countries,
in addition to the full collection of 42 countries.
4.3 Order statistics
Figures 1 and 2 present the expected order statistics of the country-specic treatment
dierences displayed as box plots and normal probability plots. These plots are dis-
played for the entire collection of 42 countries, as well as analyses restricted to the
largest 10, 15 or 20 countries. Also shown, in Figure 2 Panels B and D, are normal
probability plots corresponding to the standardised weighted least squares residuals
of Chen et al. [13], as discussed in Section 2.4. Since formal tests of heterogeneity of
treatment eects are statistically insignicant (p > 0:1 in all cases), we intend that
these graphical displays are used as a non-inferential supplement to a formal test of
heterogeneity, in which the observed variation in treatment eects is compared with
the expected variation in treatment eects. With this in mind, these gures do not
identify any remarkable dierences between what was observed and what would be
expected due to chance variation. Figure 1 clearly displays the expected increase in
treatment eect variation as more countries are included in the analysis, but does
not suggest that the observed variation is inconsistent with what was expected under
the hypothesis of homogeneity. Indeed, for the analyses involving larger numbers of
countries (Panels C and D) it appears that the PLATO study actually exhibits less
variation in country-specic treatment eects than would have been expected due to
chance. This is also evident in Figure 2 Panel C, where the shallow gradient for all but
the most extreme order statistics is indicative of smaller variation than expected.
Of particular interest is the comparison of Panels A and B of Figure 2, which
is a comparison of the normal probability plots for absolute treatment eects and
standardised treatment eects, for the analysis restricted to the largest 15 countries.
Panel A, based on absolute treatment eects, displays no departure from the expected
variation of treatment eects, with the possible exception of the smallest order statistics
that suggest lower variation than expected. On the other hand, the standardised
treatment eects displayed in Panel B show one outlying country, the USA, which
seems to have a standardised treatment eect that departs from the other countries.
This illustrates the potential for dierent qualitative messages to emerge from these
two methods.
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Figure 1: Observed and expected country-specic treatment dierences from the
PLATO study. The expected treatment dierences for the largest 10 (Panel A), 15
(Panel B), 20 (Panel C) and 42 (Panel D) countries are plotted. The dotted line de-
notes the overall observed treatment dierence.
4.4 Range of treatment eects
The expected range of treatment eects depicted in the extremities of the boxplots in
Figure 1 can be generalised to the full distribution of the range of treatment eects, as
discussed in Section 3.3. Plots of this distribution, together with the observed range
of treatment eects, are provided in Figure 3. It can be seen that the observed range
of country-specic treatment eects in the PLATO study is highly consistent with the
distribution of the range of treatment eects under the assumption of treatment eect
homogeneity. This conclusion is true regardless of whether analyses are restricted to
the largest countries or include all countries. A useful summary measure of the extent
of consistency is PE, which was described in Section 3.3. In the present context, PE
is the probability of observing a treatment eect range at least as extreme as the one
observed, under the assumption of treatment eect homogeneity. With PE = 0:55, the
overall analysis in Panel D of Figure 3 shows that a treatment eect range as large as
the one observed in the PLATO study is highly likely, and could therefore plausibly
have arisen through chance variation. The same conclusion would also be reached using
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Figure 2: Observed and expected treatment dierences from the largest 15 (Panel
A and B) and 42 (Panel C and D) countries in the PLATO study. Panels A and C
use absolute treatment eects whereas Panel B and C use the standardised weighted
least squares residuals.
the PE values restricted to the largest countries, as displayed in Panels A{C of Figure
3.
As a supplement to Figure 3, in Figure 4 we have displayed the observed and ex-
pected range of country-specic treatment eects for analyses restricted to the largest
R countries, where R ranges from 10 through 42. It is clear from Figure 4 that regard-
less of whether the expected range of treatment eects is restricted to just the very
large countries, or whether it includes the smaller countries with larger expected vari-
ation, the observed range of treatment eects is always consistent with the expected
range.
4.5 Countries favouring the control
One feature that often causes concern in MRCTs with an overall experimental treat-
ment benet, is the occurrence of inconsistent country-specic treatment eects; that
is, one or more country-specic treatment eects in the direction favouring the control
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Figure 3: Probability density of the treatment eect range for the largest 10 (Panel
A), 15 (Panel B), 20 (Panel C) and 42 (Panel D) countries in the PLATO study. The
dotted line denotes the observed range.
treatment. This was certainly a concern in PLATO, particularly because one of these
countries was the USA. In a study with as many countries as PLATO and a moderate
overall treatment benet, it is virtually certain that at least one country will have
a treatment eect favouring the control, even if the treatment eect is homogeneous
across countries. However, PLATO had 12 countries out 42 with treatment eects
favouring the control, and when restricted to the largest countries, had 7 inconsistent
eects out the largest 20 countries, 4 inconsistent eects out of the largest 15 countries,
and 3 inconsistent eects out the largest 10 countries. These numbers of inconsistent
countries may seem large, but when benchmarked against the probability distribution
of the number of treatment eects favouring the control, as described in Section 3.3,
it can be seen that they are not unusually large. Figure 5 displays these distributions,
together with the observed numbers of inconsistent countries, and the the summary
measure PE which is the probability of an observation as least as extreme as the one
observed. With PE = 0:72 for the overall analysis in Panel D of Figure 5, it can be seen
that an observation of 12 or more inconsistent countries is highly likely even under the
assumption of treatment eect homogeneity. This conclusion is not altered by restrict-
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Figure 4: The range of observed and expected country-specic treatment eects in
the PLATO study, restricting the analysis to the largest R countries, where R ranges
from 10 to 42.
ing the analysis to the largest countries, as in Panels A{C of Figure 5, all of which
also show that the observed number of inconsistent countries is not unusual relative to
what would be expected by chance. Thus, these analyses suggest that any speculation
about the causes of inconsistent country-specic treatment eects in PLATO, should
acknowledge chance variation as a highly plausible explanation.
4.6 Conclusions
Despite all of the post hoc analysis and interpretation that the PLATO study has been
subjected to, we conclude from our results that there is nothing particularly remarkable
about the spread of treatment eects across countries. In a global study as large as
the PLATO study, with over 40 countries, it is to be expected that wide variation in
treatment eects will be observed. Consistent with earlier more limited analyses [22],
our methods provide a suite of presentations suggesting that chance variation is a very
plausible explanation for the spread of country-specic treatment eects observed in
the PLATO study.
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Figure 5: Probability distribution for the number of countries favouring the control
for the largest 10 (Panel A), 15 (Panel B), 20 (Panel C) and 42 (Panel D) countries
in the PLATO study. The dotted line denotes the observed value.
Finally, we note that our analyses were repeated to investigate how the various
measures changed when a proportionally weighted overall standard error was used to
estimate the sr standard errors, as discussed in Section 3.5, instead of the individual
country-specic standard errors used in the above analyses. It was found that there
was very little dierence between this approach and the approach presented in this
section for the PLATO study.
5 Discussion
Assessment of heterogeneity of treatment eects between subgroups is a key element
of clinical trial analysis. Recently, subgroup analysis of regional dierences in MRCTs
has become a prominent issue in the literature. In this paper we provide some new
tools that aid interpretation of subgroup-specic treatment eects, and have illustrated
these using a case study from a MRCT.
When a test of interaction is underpowered, and treatment eects are seemingly
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dierent between subgroups, speculation may arise that there is heterogeneity of treat-
ment eects that was not detected by the test of interaction. The approach we propose
here is a non-inferential supplement to a formal test of interaction. A non-inferential
approach has been suggested given that the same limitation of low power for a test
of interaction will likely aect any new inferential technique one might develop to as-
sess treatment eect heterogeneity. The suite of graphical tools introduced in this
paper provide a multi-faceted visual assessment of the extent to which the observed
treatment dierences align with those that would be expected under an assumption of
treatment eect homogeneity. That is, the intent is not to assess how these methods
will perform under heterogeneity, but rather to quantify the potential extent of vari-
ation resulting from the play of chance under an assumption of homogeneity. Given
the attention heterogeneity of treatment eects across regions has received in some
MRCTs [14, 21, 23], our approach provides additional tools for evaluating the extent
of chance variation expected in a MRCT, and can be used to benchmark expectations
and pre-empt any over-interpretation. The graphical nature of our methods make it
amenable for interpretation by all stakeholders including non-statisticians.
Treatment dierences in typical clinical trial subgroups such as age and sex may
present a plausible biological mechanism that explains the dierence. However, treat-
ment dierences between regions are often more complex to understand because region
is a composite of many variables that can potentially inuence the outcomes of an in-
tervention [4]. Thorough evaluation of potential treatment dierences between regions
at the design stage of a study is critical, and can assist with the interpretation of any
apparent heterogeneity that emerges at the analysis stage.
Our methods dier from a recently published method by Chen et al. [13] in that we
use the observed treatment dierences whereas Chen et al. [13] use the standardised
treatment dierences as dened by the weighted least squares residuals. Although this
dierence may seem trivial, the results and their interpretation can be quite dierent
as the ordering proposed by Chen et al. [13] depends on the relative magnitude of
the departure of the region-specic treatment eect from the overall eect, compared
with its standard error. We advocate the use of the observed treatment dierences as
these are required in practice for such activities as cost-eectiveness analyses and risk
stratication in addition to the direct relevance they have for the physician and the
patient.
In conclusion, our methods provide a non-inferential yet visually informative sum-
mary of the subgroup-specic variation in treatment eects that can arise as an artefact
of chance. The appeal of these methods is their broad applicability, not just to global
clinical trials as discussed here but also to other types of subgroup analysis, as well as
the accessibility of the visual displays to all stakeholders including non-statisticians.
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